Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/117689
Citations | ||
Scopus | Web of Science® | Altmetric |
---|---|---|
?
|
?
|
Type: | Journal article |
Title: | Treatment with high dose salicylates improves cardiometabolic parameters: meta-analysis of randomized controlled trials |
Author: | Baye, E. Naderpoor, N. Misso, M. Teede, H. Moran, L.J. de Courten, B. |
Citation: | Metabolism: clinical and experimental, 2017; 71:94-106 |
Publisher: | Elsevier |
Issue Date: | 2017 |
ISSN: | 0026-0495 1532-8600 |
Statement of Responsibility: | Estifanos Baye, Negar Naderpoor, Marie Misso, Helena Teede, Lisa J. Moran, Barbora de Courten |
Abstract: | There is conflicting evidence regarding the efficacy of high dose salicylates in improving cardiometabolic risk in healthy and type 2 diabetes patients. We aimed to determine whether treatment with salicylates at an anti-inflammatory dose (≥1g daily) would improve cardiometabolic risk in healthy individuals and type 2 diabetes patients, compared to placebo.Medline, Medline-in-process, Embase, and all EBM databases were searched for studies published up to December 2016. Twenty-eight articles from 24 studies comprising 1591 participants were included. Two reviewers independently assessed the risk of bias and extracted data from included studies. Meta-analyses using random-effects model were used to analyze the data.High dose salicylates (≥3g/d) decreased fasting glucose (MD -0.4mmol/l, 95% CI -0.54, -0.27) and glucose area under the curve (MD -0.41mmol/l, 95% CI -0.81, -0.01). Salicylates (≥3g/d) also increased fasting insulin (MD 2.4 μU/ml, 95% CI 0.3, 4.4), 2-h insulin (MD 25.4 μU/ml, 95% CI 8.2, 42.6), insulin secretion (MD 79.2, 95% CI 35, 123) but decreased fasting C-peptide (MD -0.11nmol/l, 95% CI -0.2, -0.04), insulin clearance (MD -0.26l/min, 95% CI -0.36, -0.16) and triglycerides (MD -0.36mmol/l, 95% CI -0.51, -0.21) and increased total adiponectin (MD 1.97μg/ml, 95% CI 0.99, 2.95). A lower salicylate dose (1-2.9g) did not change any cardiometabolic parameters (p>0.1). No significant difference was observed between those receiving salicylates and placebo following withdrawal due to adverse events.High dose salicylates appear to improve cardiometabolic risk factors in healthy individuals and type 2 diabetes patients.CRD42015029826. |
Keywords: | SalicylatesType 2 diabetes; cardiovascular disease; chronic inflammation; meta-analysis |
Rights: | © 2017 Elsevier Inc. All rights reserved. |
DOI: | 10.1016/j.metabol.2017.03.006 |
Published version: | http://dx.doi.org/10.1016/j.metabol.2017.03.006 |
Appears in Collections: | Aurora harvest 8 Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.